Calling the Shots:
How Immune Checkpoint Inhibitors are Redefining CSCC
Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.
McLean LS, et al. Drugs Aging. 2024;41(3):271-281.
What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper.
Loh KP, et al. J Oncol Pract. 2018;14(2):85-94.
American Geriatrics Society position statement: Making medical treatment decisions for unrepresented older adults.
Dixon JD, et al. J Am Geriatr Soc. 2025;73(5):1353-1364.
Immune-related adverse events of immune checkpoint inhibitors: a review.
Yin Q, et al. Front Immunol. 2023;14:1167975.
Recent advances in the diagnosis and management of high-risk cutaneous squamous cell carcinoma.
Dessinioti C, et al. Cancers (Basel). 2022;14(14):3556.
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.
Karia PS, et al. J Clin Oncol. 2014;32(4):327-34.
Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma.
Rischin D, et al. N Engl J Med. 2025;393(8):774-785.
Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).
Koyfman SA, et al. J Clin Oncol. 2025;43(16 suppl):6000.
Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.
Claveau J, et al. Curr Oncol. 2020;27(4):e399-e407.
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, et al. J Am Acad Dermatol. 2025;92(1):68-77.
Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.
Munoz-Couselo E, et al. J Clin Oncol. 2024;42(16suppl):9554.
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.
Ruiz ES, et al. J Am Acad Dermatol. 2026;94(1):48-56.
Neoadjuvant cemiplimab for stage ii to iv cutaneous squamous-cell carcinoma.
Gross ND, et al. N Engl J Med. 2022;387:1557-1568.
Guidelines
NCCN Guidelines®: Squamous Cell Skin Cancer, version 2.2026.
Clinician Resources
Advanced CSCC Clinician Pocket Guide
Download and print this helpful pocket guide.
irAE Management Guide
Download and print this helpful management guide.
American Academy of Dermatology
Association of Cancer Care Centers
Immunotherapy for Older Adults With Metastatic cSCC
Module 1
| Faculty: | David M. Miller, MD, PhD; Krista M. Rubin, MS, FNP-BC |
| Release: | 08/31/2026 |
| Expiration: | 08/31/2027 |
Anticipating and Managing Immune-Related Adverse Events
Module 2
| Faculty: | David M. Miller, MD, PhD; Krista M. Rubin, MS, FNP-BC |
| Release: | 09/14/2026 |
| Expiration: | 09/14/2027 |
Defining High Risk and the Role of Adjuvant Immunotherapy
Module 3
| Faculty: | David M. Miller, MD, PhD; Vishal Anil Patel, MD |
| Release: | 09/28/2026 |
| Expiration: | 09/28/2027 |
Individualizing Immunotherapy for Metastatic cSCC
Module 4
| Faculty: | David M. Miller, MD, PhD; Vishal Anil Patel, MD |
| Release: | 10/12/2026 |
| Expiration: | 10/12/2027 |
